Synthesis and determination of acute and chronic pain activities of 1-[1-(3-methylphenyl)(tetralyl)]piperidine as a new derivative of phencyclidine via tail immersion and formalin tests

Arzneimittel-Forschung/Drug Research

Volumn 60, Issue 1, 2010, Pages 30-35

  Ahmadi, Abbas ^a   Khalili, Mohsen ^b   Mihandoust, Farnaz ^a   Barghi, Leila ^a  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b SHAHED UNIVERSITY   (Iran)

Author keywords

1 Tetralone derivatives, analgesic effects, formalin test, tail immersion test; CAS 1867 66 9; CAS 956 90 1; Ketamine; Phencyclidine

Indexed keywords

1 [1 (3 METHYLPHENYL)(TETRALYL)]PIPERIDINE; CAS 1867 66 9; CAS 956 90 1; KETAMINE; PHENCYCLIDINE DERIVATIVE; PIPERIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CHRONIC PAIN; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DETERMINATION; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; NONHUMAN; RAT;

EID: 74949120181     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296245     Document Type: Article

References (35)

1. Greifenstein FE, Yoshitake J, De Vaulet M, Gajewski JE. A study of 1-arylcyclohexylamine for anesthesia. Anesth Analg. 1958;37:283-4.
2. Chen G, Ensor CR, Russell D, Bohner B. The pharmacology of 1-(1-phenylcyclohexyl) piperidine. HCl. J. Pharmacol. Exp Ther. 1959;127:241-50.
3. Chen G, Weston JK. The analgesic and anesthetic effects of 1-(1-phenylcyclohexyl) piperidine.HCl on the monkey. Anesth Analg. 1960;39:132-7.
4. Kemp JA, Foster AC, Wong EHF. Non-competitive antagonists of excitatory amino acid receptors. Trends Neurosci. 1987;10:294-8.
5. Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, Sesma MA. NMDA antagonist neurotoxicity: mechanism and prevention. Science. 1991;254(5037):1515-8.
6. Kapur S, Seeman P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D (2) and serotonin 5-HT (2) receptors-implications for models of schizophrenia. Mol Psychiatry. 2002;7(8):837-44.
7. Domino EF, Chodoff P, Corssen G. Pharmacologic effects of Ci-581, a new dissociative anesthetic, in man. Clin Pharmacol Ther. 1965;6:279-91.
8. Brooks WJ, Petit TL, LeBoutillier JC. Effects of chronic administration of NMDA antagonists on synaptic development. Synapse. 1997;26:104-13.
9. Hetman M, Kharebava G. Survival signaling pathways activated by NMDA receptors. Curr Top Med Chem. 2006;6:787-99.
10. Lipton SA. Pathologically activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation. Curr Drug Targets. 2007;8:621-32.
11. Schrattenholz A, Soskic V. NMDA receptors are not alone: dynamic regulation of NMDA receptor structure and function by neuregulins and transient cholesterol-rich membrane domains leads to disease-specific nuances of glutamate-signaling. Curr Top Med Chem. 2006;6:663-86.
12. Anis NA, Berry SC, Burton NR, Lodge D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol. 1983;79:565-75.
13. MacDonald JF, Bartlett MC, Mody I, Pahapill P, Reynolds JN, Salter MW, et al. Actions of ketamine, phencyclidine and MK-801 on NMDA receptor currents in cultured mouse hippocampal neurones. J Physiol. 1991;432:483-508.
14. Monaghan DT, Bridges RJ, Cotman CW. The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu Rev Pharmacol Toxicol. 1989;29:365-402.
15. Orser BA, Pennefather PS, MacDonald JF. Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors. Anesthesiology. 1997;86:903-17.
16. Kamenka JM, Chiche B, Goudal R, Geneste P, Vignon J, Vincent JP, et al. Chemical synthesis and molecular pharmacology of hydroxylated 1-(1-phenylcyclohexyl) piperidine derivatives. J Med Chem. 1982;25:431-435.
17. Al-Deeb OA. Synthesis and analgesic activity of new phencyclidine derivatives. Arzneimittelforschung. 1994;44(10):1141-4.
18. Ahmadi A, Mahmoudi A. Synthesis and biological properties of 2-hydroxy-1-(1-phenyltetralin)piperidine and some of its intermediates as derivatives of phencyclidine Arzneimittelforschung. 2005;55(9):528-32.
19. Al-Deeb OA. New analgesics derived from the phencyclidine analogue thiencyclidine. Arzneimittelforschung. 1996;46(5):505-8.
20. Ahmadi A, Shafiezadeh M, Fathollahi Y, Darwich MR, Mahmoudi A, Bahmani M, et al. Synthesis with improved yield and study on the analgesic effect of 2-hydroxyphencyclidine. Arzneimittelforschung. 2005;55(3):172-6.
21. Geneste P, Kamenka JM, Ung SN, Herrmann P, Goudal R, Trouiller G. Determination conformationnelle de derives de la phencyclidine en vue d'une corrélation structure-active. Eur J Med Chem. 1979;14:301-8.
22. Ahmadi A, Khalili M, Abbassi S, Javadi M, Mahmoudi A, Hajikhani R. Synthesis and study on analgesic effects of 1-[1-(4-methylphenyl)(cyclohexyl)]4- piperidinol and 1-[1-(4-methoxyphenyl)(cyclohexyl)]4-piperidinol as two new phencyclidine derivatives. Arzneimittelforschung. 2009;59(4):202-6.
23. Kaorv H. O-H stretching absorption and conformation of the β-methyl derivatives of 1-tetralol, 4-chromanol, 4-thiochromanol, and 4-thiochromanol 1,1-dioxide. Bull Chem Soc Japan. 1974;47(10):2607-8.
24. Geneste P, Kamenka JM, Dessapt P. Method for stereoselective production of substituted cyclohexylcyanhydrines. Bull Soc Chim Fr. 1980;II:187-91.
25. Hamura H, Yoshida M, Shimizu K, Matsukura T, Suzuki H, Narita M, et al. Antinociceptive effect of the combination of pentazocine with morphine in the tail-immersion and scald-pain tests in rats. Jpn J Pharmacol. 2000;83(4):286-92.
26. Padi SSV, Kulkarni S. K. Minocycline prevents the development of neuropathic pain, but not acute pain: Possible anti-inflammatory and antioxidant mechanisms. Eur J Pharmacol. 2008;601:79-87.
27. Ibrahim MM, Rude ML, Stagg NJ, Mata HP, Lai J, Vanderah TW, et al. CB2 cannabinoid receptor mediation of antinociception. Pain. 2006;122:36-42.
28. Dubuisson D, Dennis SG. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain. 1977;4(2):161-74.
29. Jones LA, Beaver RW, Schmoeger TL, Ort JF, Leander JD. Isolation, identification and synthesis of compounds cosynthesized in the preparation of phencyclidine. J Org Chem. 1981;46:3330-3.
30. Shebley M, Jushchyshyn MI, Hollenberg F. Selective pathways for the metabolism of phencyclidine by cytochrome P450 2B enzymes: identification of electrophilic methabolites, glutathione and N-acetyl cysteine adducts. Drug Metab Dispos. 2006;34(3):375-83.
31. Kamenka JM, Hamon J, Vignon J, inventors; Societe de conseils de recherché et d'applications scientfiques (S.C.R.A.S.) (FR), assignee. Phencyclidine derivatives, preparation method and pharmaceutical compositions containing same. United States patent US 6,342,511B1. 2002.
32. Qian J, Brown SD, Carlton SM. Systemic ketamine attenuates nociceptive behaviors in a rat model of peripheral neuropathy. Brain Res. 1996;715:51-62.
33. Shimoyama M, Shimoyama N, Gorman AL. Oral ketamine is antinociceptive in the rat formalin test: role of the metabolite, nor ketamine. Pain. 1999;81:85-93.
34. Rabben T, Skjelbred P, Oye I. Prolonged analgesic effect of ketamine, an N-methyl-D-asparate receptor inhibitor, in patients with chronic pain. J Pharmacol Exp Ther. 1999;289:1060.
35. Bonnefont J, Alloui A, Chapuy E, Clottes E, Eschalier A. Orally administered paracetamol does not act locally in the rat formalin test: evidence for a supraspinal, serotonin-dependent antinociceptive mechanism. Anesthesiology. 2003;99(4):976-81.